ADXN

Addex Therapeutics Ltd (ADXN) | Rumor.io

Addex Therapeutics

ADXN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,506

Bullish sentiment (50-day avg)97%

Price to earnings ratio-0.39

Market capitalization3.6M

Earnings per share-8.77

Dividend yield (TTM)—

Revenue (annual)30K

Net income (annual)-6.7M

Social

What share of all stock conversation is about ADXN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 28

Addex Therapeutics Ltd's stock price has dropped, but some investors see this as an opportunity to buy, citing the company's strong fundamentals and the potential for long-term upside.
The recent decline in Addex Therapeutics Ltd's stock price is seen as a buying opportunity by some investors, who believe that the market overreacted to the news and that the company's thesis remains intact.
The CEO of Addex Therapeutics Ltd, Tim Dyer, has maintained his share position despite the recent decline, which some investors see as a positive sign for the company's future prospects.

Generated by AI

Sentiment

Of the messages about ADXN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.89% +2.43
Bearish	—	—	—	3.11% -2.43

Bullish· Aug 21

The asset's low price of $5.75 has been broken, and it's now trading above this level, with a target of $6.95 and potentially reaching $7.5/9.5/12.
The asset has a low float of 1 million shares, with a significant amount of volume traded already, indicating a high likelihood of price appreciation.
The asset is trading at its 50-day consistent level, which could be a signal for a potential breakout and subsequent price increase.

Bearish· Sep 11

The market capitalization of $ADXN is over $17 million, which some consider a red flag for a "scam".
The asset has a relatively small float, which could lead to a sharp price drop if many holders try to sell at once.
$ADXN's price action over the past 5 years has been largely stagnant, with no significant upward momentum.

Generated by AI

Topics

Of the messages about ADXN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	48.46%
Technical Analysis	—	0%	0%	51.54%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Apr 3

Addex Therapeutics (ADXN) has partnered with Perceptive Advisors to launch Neurosterix, a company focused on developing allosteric modulators for neurological disorders, with a $63 million investment.
Addex will receive CHF5 million and a 20% equity interest in Neurosterix, while retaining its partnerships with Janssen and Indivior, as well as unpartnered clinical stage assets.
The deal is expected to significantly reduce Addex's operating costs and extend its cash runway beyond 2026, with the potential for high revenues from its programs with J&J and Indivior.

Technical Analysis· Aug 27

The Relative Strength Index (RSI) for $ADXN is relatively low, and a 50 MA crossover is occurring, with a flag forming, suggesting a potential buying opportunity.
The current price of $ADXN is above the VWAP, and closing strong, with a target of $15-$19.5 expected if it breaks the 11.61 resistance.
The chart of $ADXN is looking good, with a potential break of 12 and a target of $15 by EOD, with extension targets at 12.75 and 14, and stops near 11.90-12.

Generated by AI

Community

Of the messages about ADXN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	63.16%	65%	34.44%
Newcomers	0%	36.84%	35%	65.56%

Regulars· Apr 29

Addex Therapeutics' Phase 2 epilepsy study for ADX71149 did not achieve statistical significance for the primary endpoint, disappointing investors.
The company's CEO, Tim Dyer, remains focused on advancing its portfolio of allosteric modulator programs towards clinical studies.
The failed study resulted in a significant price drop, with ADXN down around 50% on the day of the announcement.

Newcomers· Aug 28

Newcomers to Addex Therapeutics (ADXN) see this dip as an opportunity to buy shares, citing the company's thesis and long-term potential.
Many newcomers believe that market panic and volatility create buying signals for Addex, with some even taking the opportunity to add to their position.
Some newcomers are focusing on the CEO's ownership history, noting that Tim Dyer's personal stake in the company remained intact during the recent period, which they see as a positive sign for investors.

Generated by AI

Addex Therapeutics (NASDAQ:ADXN) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

1d agoBenzinga

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

2d agoYahoo Finance

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage...

1mo agoBarchart.com

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

2mo agoBarchart.com

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

2mo agoYahoo Finance

Also Discussed

Investors talking about ADXN also mention

#	Name	Attention
1	Intelligent Living Application Group Inc.ILAG	0%new
2	United Maritime CorporationUSEA	0%0
3	Singularity Future Technology Ltd.SGLY	0%0
4	Surrozen, Inc.SRZN	0%0
5	TRML - Tourmaline Bio, Inc.	——
6	Expion360 Inc.XPON	0%0
7	HOFV - Hall of Fame Resort & Entertainment Company	——
8	WEBs Technology XLK Defined Volatility ETFDVXK	0%0
9	JPMorgan Fundamental Data Science Small Core ETFSCDS	0%0
10	DBTX - Decibel Therapeutics, Inc.	——

Addex Therapeutics Ltd

Healthcare
Biotechnology

Addex Therapeutics Ltd ADR is a Swiss biopharmaceutical company focused on discovering, developing, and commercializing orally available small-molecule drugs for neurological disorders. The company specializes in allosteric modulators, a class of compounds designed to influence receptor activity in a more selective way, and its research platform centers on G-protein coupled receptors and related targets. Addex Therapeutics Ltd ADR’s current portfolio includes clinical-stage and discovery programs addressing conditions such as movement disorders, epilepsy, addiction, and other central nervous system diseases. Through this pipeline, the company plays a role in advancing innovative therapies for areas with significant unmet medical need. Addex Therapeutics Ltd ADR is based in Geneva, Switzerland, and operates as a development-stage biotechnology company with a strong emphasis on research-driven drug discovery and translational medicine.

Website

Location

Chemin des Mines, 9

Geneva, 1202

Switzerland

Social

What share of all stock conversation is about ADXN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 28

Addex Therapeutics Ltd's stock price has dropped, but some investors see this as an opportunity to buy, citing the company's strong fundamentals and the potential for long-term upside.
The recent decline in Addex Therapeutics Ltd's stock price is seen as a buying opportunity by some investors, who believe that the market overreacted to the news and that the company's thesis remains intact.
The CEO of Addex Therapeutics Ltd, Tim Dyer, has maintained his share position despite the recent decline, which some investors see as a positive sign for the company's future prospects.

Generated by AI

Sentiment

Of the messages about ADXN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	96.89% +2.43
Bearish	—	—	—	3.11% -2.43

Bullish· Aug 21

The asset's low price of $5.75 has been broken, and it's now trading above this level, with a target of $6.95 and potentially reaching $7.5/9.5/12.
The asset has a low float of 1 million shares, with a significant amount of volume traded already, indicating a high likelihood of price appreciation.
The asset is trading at its 50-day consistent level, which could be a signal for a potential breakout and subsequent price increase.

Bearish· Sep 11

The market capitalization of $ADXN is over $17 million, which some consider a red flag for a "scam".
The asset has a relatively small float, which could lead to a sharp price drop if many holders try to sell at once.
$ADXN's price action over the past 5 years has been largely stagnant, with no significant upward momentum.

Generated by AI

Topics

Of the messages about ADXN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	48.46%
Technical Analysis	—	0%	0%	51.54%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Apr 3

Addex Therapeutics (ADXN) has partnered with Perceptive Advisors to launch Neurosterix, a company focused on developing allosteric modulators for neurological disorders, with a $63 million investment.
Addex will receive CHF5 million and a 20% equity interest in Neurosterix, while retaining its partnerships with Janssen and Indivior, as well as unpartnered clinical stage assets.
The deal is expected to significantly reduce Addex's operating costs and extend its cash runway beyond 2026, with the potential for high revenues from its programs with J&J and Indivior.

Technical Analysis· Aug 27

The Relative Strength Index (RSI) for $ADXN is relatively low, and a 50 MA crossover is occurring, with a flag forming, suggesting a potential buying opportunity.
The current price of $ADXN is above the VWAP, and closing strong, with a target of $15-$19.5 expected if it breaks the 11.61 resistance.
The chart of $ADXN is looking good, with a potential break of 12 and a target of $15 by EOD, with extension targets at 12.75 and 14, and stops near 11.90-12.

Generated by AI

Community

Of the messages about ADXN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	63.16%	65%	34.44%
Newcomers	0%	36.84%	35%	65.56%

Regulars· Apr 29

Addex Therapeutics' Phase 2 epilepsy study for ADX71149 did not achieve statistical significance for the primary endpoint, disappointing investors.
The company's CEO, Tim Dyer, remains focused on advancing its portfolio of allosteric modulator programs towards clinical studies.
The failed study resulted in a significant price drop, with ADXN down around 50% on the day of the announcement.

Newcomers· Aug 28

Newcomers to Addex Therapeutics (ADXN) see this dip as an opportunity to buy shares, citing the company's thesis and long-term potential.
Many newcomers believe that market panic and volatility create buying signals for Addex, with some even taking the opportunity to add to their position.
Some newcomers are focusing on the CEO's ownership history, noting that Tim Dyer's personal stake in the company remained intact during the recent period, which they see as a positive sign for investors.

Generated by AI

Addex Therapeutics

Social

Aug 28

Sentiment

Bullish· Aug 21

Bearish· Sep 11

Topics

Announcements· Apr 3

Technical Analysis· Aug 27

Community

Regulars· Apr 29

Newcomers· Aug 28

News

Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Addex Therapeutics (NASDAQ:AD

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Also Discussed

Addex Therapeutics Ltd

Company Information

Location

News

Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Addex Therapeutics (NASDAQ:AD

Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Also Discussed

Social

Aug 28

Sentiment

Bullish· Aug 21

Bearish· Sep 11

Topics

Announcements· Apr 3

Technical Analysis· Aug 27

Community

Regulars· Apr 29

Newcomers· Aug 28